NAVLE Multisystemic

Bovine Fat Cow Syndrome and Subclinical Fatty Liver Study Guide

📅 March 28, 2026 ⏱ 25 min read

Fat cow syndrome (FCS) and hepatic lipidosis (fatty liver) are major metabolic disorders affecting periparturient dairy cattle.

Overview and Clinical Importance

Fat cow syndrome (FCS) and hepatic lipidosis (fatty liver) are major metabolic disorders affecting periparturient dairy cattle. These conditions represent a spectrum of the same pathophysiological process, characterized by excessive accumulation of triacylglycerol (TAG) in hepatocytes due to negative energy balance (NEB) around calving. Fat cow syndrome specifically refers to the clinical manifestation in overconditioned cows, while subclinical fatty liver affects up to 50% of high-producing dairy cows in early lactation without overt clinical signs. These conditions are economically devastating, costing the U.S. dairy industry an estimated $60 million annually due to decreased milk production, impaired fertility, increased disease susceptibility, and death.

Grade	Liver TAG Content	Fat % Cell Volume	Clinical Significance
Normal	Less than 1%	Less than 5%	No clinical signs; normal function
Mild	1-5%	5-20%	Subclinical; decreased fertility and immune function
Moderate	5-10%	20-40%	Ketosis; decreased milk production; increased disease risk
Severe	Greater than 10%	Greater than 40%	Clinical fatty liver syndrome; liver failure; hepatic encephalopathy; poor prognosis (greater than 35% fat = high mortality)

Etiology and Pathophysiology

The Transition Period and Negative Energy Balance

The transition period (3 weeks prepartum to 3 weeks postpartum) represents the most metabolically challenging time for dairy cows. During this period, dry matter intake (DMI) decreases by 30% or more while energy demands for lactation increase dramatically. This creates a state of negative energy balance (NEB), triggering mobilization of body fat reserves to meet energy demands.

Mechanism of Hepatic Lipid Accumulation

When adipose tissue is mobilized, non-esterified fatty acids (NEFAs) are released into the bloodstream. The liver takes up approximately 15-20% of circulating NEFAs. Under normal conditions, hepatocytes process NEFAs through three pathways:

Complete oxidation in the TCA cycle for energy production
Partial oxidation to ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone)
Re-esterification to triacylglycerol (TAG) and export as very low-density lipoproteins (VLDL)

High-YieldThe rate-limiting step in bovine fatty liver is the EXTREMELY LIMITED capacity of ruminant hepatocytes to export TAG as VLDL compared to non-ruminants. This is the key species-specific difference that makes cattle uniquely susceptible to hepatic lipidosis.

When NEFA uptake exceeds the liver's capacity for oxidation and VLDL export, excess NEFAs are re-esterified and stored as TAG within hepatocytes. Normal bovine liver contains less than 1% fat (or less than 5% TAG as percentage of wet weight). When TAG accumulation exceeds 10% of liver wet weight, clinical dysfunction begins to manifest.

Hormonal Regulation

The hormonal milieu around parturition promotes fat mobilization. Key hormonal changes include: decreased insulin and IGF-1 concentrations, increased growth hormone (uncoupled from IGF-1 axis), elevated glucagon and catecholamines, and development of insulin resistance in peripheral tissues. These changes activate hormone-sensitive lipase in adipose tissue, triggering lipolysis and NEFA release. Elevated estrogen concentrations around parturition also increase hepatic TAG synthesis.

System	Clinical Findings
General	Depression, lethargy, weakness, anorexia or inappetence, progressive debilitation, rapid loss of body condition (may lose greater than 1 BCS in first month)
Metabolic	Ketonuria and ketonemia (sweet acetone breath), marked decrease in milk production, hypoglycemia
Neurological (Severe)	Hepatic encephalopathy: head pressing, circling, ataxia, blindness, aggression, recumbency (downer cow)
Secondary Infections	Fever (due to concurrent mastitis, metritis), retained fetal membranes, increased susceptibility to infectious diseases

Classification of Hepatic Lipidosis Severity

Fatty liver is classified based on hepatic TAG content as percentage of liver wet weight. The clinical significance and associated complications increase with severity.

Parameter	Normal Range	Risk Threshold	Clinical Significance
NEFA	Less than 0.4 mEq/L	Greater than 0.7 mEq/L prepartum; Greater than 1.0 mEq/L postpartum	Direct indicator of fat mobilization; greater than 0.6 mmol/L associated with fatty liver
BHB (Beta-hydroxybutyrate)	Less than 1.0 mmol/L	1.2-2.9 mmol/L = subclinical ketosis; Greater than 2.9 mmol/L = clinical ketosis	More accurate postpartum indicator of hepatic lipidosis severity than NEFA
AST	78-132 U/L	Elevated with hepatocyte damage	Correlates with severity of fatty liver; not liver-specific
GGT	6-17 U/L	Elevated with cholestasis	Less specific; indicates bile duct compression by lipid-laden hepatocytes
Total Bilirubin	0.1-0.5 mg/dL	Elevated	Correlates with degree of hepatic lipidosis
Glucose	45-75 mg/dL	Decreased	Hypoglycemia due to impaired hepatic gluconeogenesis

Risk Factors

Primary Risk Factors

Overconditioning at calving (BCS greater than 3.5-4.0): Obese cows have larger fat reserves to mobilize and experience more pronounced feed intake depression
High milk production: Greater energy demands create more severe NEB
Multiparous cows: Higher susceptibility compared to heifers
Decreased DMI prepartum: A 20% or greater drop in intake before calving significantly increases risk

Secondary Risk Factors

Dystocia and twin pregnancies
Retained fetal membranes and metritis
Subclinical hypocalcemia (impairs insulin secretion)
Lameness during the dry period (decreases standing and eating time)
Poor quality or butyric acid-containing silage
Heat stress
Any concurrent disease causing anorexia

NAVLE TipThe fat cow syndrome is often a HERD PROBLEM rather than an individual cow problem. When you see multiple periparturient cows presenting with signs of metabolic disease, think about dry cow nutrition and management.

Treatment	Dose/Route	Mechanism	Notes
Propylene Glycol	250-500 mL PO BID for 3-5 days	Glucose precursor; triggers insulin release to suppress lipolysis	First-line treatment; best given as oral drench, not mixed in feed
IV Dextrose (50%)	500 mL IV bolus; or continuous infusion up to 60 g/hour	Immediate glucose supply; stimulates insulin secretion	Effect lasts only 80-100 min after bolus; combine with propylene glycol for sustained effect
Glucocorticoids	Dexamethasone 10-20 mg IM or IV every 48 hours	Enhances gluconeogenesis; improves appetite	Controversial due to potential lipolytic effect; short-term use appears safe
Glycerol	Up to 500 g PO BID	Glucose precursor	More palatable than propylene glycol but requires larger doses
B Vitamins (B12, Butaphosphan)	Per label; IM or IV	Supports gluconeogenesis; hepatoprotective	Beneficial as adjunct therapy; IV choline/methionine not effective (rumen degradation)

Clinical Signs and Presentation

Subclinical Fatty Liver

Subclinical fatty liver affects up to 50% of high-producing dairy cows in early lactation. By definition, there are no overt clinical signs, but affected cows may show: reduced milk production below expected levels, delayed return to estrus and decreased fertility, increased susceptibility to infectious diseases (mastitis, metritis), and predisposition to other metabolic disorders (ketosis, displaced abomasum).

Clinical Fat Cow Syndrome

Clinical signs typically appear within the first 1-3 weeks postpartum and include:

High-YieldFat cow syndrome has NO PATHOGNOMONIC CLINICAL SIGNS. The key diagnostic clue is an OVERCONDITIONED COW (BCS greater than 4) in the periparturient period with depression, anorexia, and ketosis that responds poorly to standard ketosis treatment.

Condition	Relationship to Fatty Liver
Ketosis	Fatty liver PRECEDES and predisposes to ketosis; both result from NEB but fatty liver impairs gluconeogenesis worsening hypoglycemia
Displaced Abomasum (LDA)	Common concurrent finding; both conditions share risk factors (decreased DMI, NEB)
Retained Fetal Membranes	Impaired immune function from fatty liver increases risk; RFM causes anorexia worsening NEB
Metritis	Immunosuppression from fatty liver increases susceptibility; concurrent infection worsens anorexia
Mastitis	Elevated NEFA impairs neutrophil function; increased susceptibility to intramammary infection
Milk Fever (Hypocalcemia)	Subclinical hypocalcemia impairs insulin secretion promoting lipolysis and fatty liver development
Poor Fertility	Even mild fatty liver delays return to estrus; impaired progesterone production; early embryonic death

Diagnosis

Serum Biomarkers

NAVLE TipFor NAVLE, remember that NEFA is the best PREPARTUM indicator of risk (reflects current fat mobilization), while BHB is the better POSTPARTUM indicator of fatty liver severity (reflects hepatic ketogenesis from overwhelmed fatty acid oxidation).

Definitive Diagnosis: Liver Biopsy

Liver biopsy remains the gold standard for diagnosing hepatic lipidosis. It is a minimally invasive procedure performed in the right 11th or 12th intercostal space. Liver TAG content can be determined by chemical extraction and gravimetric analysis. A practical field test involves flotation of the biopsy sample in copper sulfate solutions of varying specific gravity (samples with greater than 34% fat will float in solution with specific gravity of 1.025).

Ultrasonography

Hepatic ultrasonography provides a non-invasive diagnostic option. Fatty liver appears as increased echogenicity (hyperechoic) of the hepatic parenchyma compared to the renal cortex. Computer-aided ultrasound diagnosis (CAUS) can estimate liver TAG content with approximately 80% accuracy. Limitations include operator dependence and inability to detect mild fatty liver.

Pathology Findings

Gross Pathology

At necropsy, the liver of affected cows is enlarged, rounded (loss of sharp edges), yellow-orange to tan in color, and greasy or friable in texture. The liver may float in formalin due to high fat content. Cut surfaces appear pale yellow with a greasy feel. The gallbladder may be distended with yellow-orange bile.

Histopathology

Microscopic examination reveals diffuse macrovesicular steatosis with large, clear, intracytoplasmic lipid vacuoles that displace the nucleus peripherally (signet ring appearance). Hepatocytes may show ballooning degeneration. Centrilobular distribution is common. Severe cases may show hepatocyte necrosis, fibrosis, and bile duct proliferation.

Treatment

Treatment aims to: (1) increase glucose supply to suppress lipolysis, (2) enhance hepatic glucose production, and (3) support liver function. Prognosis is guarded to poor for severe cases (liver TAG greater than 35% by weight).

High-YieldLipotropic agents (choline, methionine, inositol) that work in non-ruminants have NOT been proven effective in cattle when given IV or orally because they are degraded in the rumen. Only RUMEN-PROTECTED choline has shown benefit for prevention (not treatment).

Prevention

Prevention is MORE EFFECTIVE than treatment. The critical window is 1 week before through 1 week after calving.

Nutritional Management

Optimal BCS at calving: Target BCS 3.0-3.5 (5-point scale); avoid overconditioning (BCS greater than 4.0) in late lactation and dry period
Maintain DMI: Feed high-quality, palatable forages; minimize feed intake depression prepartum
Propylene glycol: 300-600 mL/day PO as drench for final week prepartum in at-risk cows; proven to reduce plasma NEFA and fatty liver severity
Rumen-protected choline: 15-20 g/day prepartum and postpartum; enhances hepatic VLDL export
Monensin: Oral slow-release bolus for dry cows; modulates rumen fermentation to increase propionate (glucogenic); reduces ketosis and fatty liver risk

Management Practices

Minimize stress at calving (adequate space, clean environment, minimize group changes)
Monitor close-up dry cows and fresh cows closely
Separate dry cows from lactating herd to avoid competition and optimize nutrition
Early identification and treatment of concurrent diseases

Associated Conditions and Complications

Hepatic lipidosis is associated with increased risk of multiple periparturient diseases due to impaired immune function and metabolic dysfunction:

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →